Planegg – Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at four upcoming investors, business development and scientific conferences:
Biologics & Biosimilars Congress
Date: 5 – 6 March 2018
Location: Berlin, Germany
Annual ROTH Conference
Date: 11 – 13 March 2018
Location: Orange County, CA, USA
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation for investors on 13 March.
BIO-Europe Spring
Date: 12 – 14 March 2018
Location: Amsterdam, Netherlands
Annual Needham Healthcare Conference
Date: 27 – 28 March 2018
Location: New York, USA
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation on 28 March.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit https://medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01,
email: investor@medigene.com